Savara gets FDA breakthrough status despite large, late-stage failure
Savara watched their stock crater in June as they announced a late-stage failure on their lead compound. But now, based on the same Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
